| 3.22 -0.01 (-0.31%) | 12-01 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.21 | 1-year : | 4.66 |
| Resists | First : | 3.6 | Second : | 3.99 |
| Pivot price | 3.39 |
|||
| Supports | First : | 2.99 | Second : | 2.48 |
| MAs | MA(5) : | 3.15 |
MA(20) : | 3.47 |
| MA(100) : | 3.16 |
MA(250) : | 3.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.9 |
D(3) : | 12.3 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 9.01 | Low : | 1.86 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BNTC ] has closed above bottom band by 37.7%. Bollinger Bands are 3.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.47 - 3.49 | 3.49 - 3.5 |
| Low: | 3.02 - 3.04 | 3.04 - 3.06 |
| Close: | 3.15 - 3.18 | 3.18 - 3.21 |
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Thu, 30 Nov 2023
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a ... - BioSpace
Thu, 30 Nov 2023
Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO ... - Yahoo Finance
Fri, 17 Nov 2023
2023-11-17 | NDAQ:BNTC | Press Release | Benitec Biopharma Inc - Stockhouse Publishing
Mon, 13 Nov 2023
Benitec Biopharma Releases First Quarter 2024 Financial Results ... - Yahoo Finance
Fri, 18 Aug 2023
JANUS HENDERSON GROUP PLC Acquires New Stake in Benitec ... - Yahoo Finance
Tue, 08 Aug 2023
Benitec Biopharma Inc. Announces Pricing of $30 Million ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 68 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.026e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -27 % |
| Return on Assets (ttm) | 166.6 % |
| Return on Equity (ttm) | -56.4 % |
| Qtrly Rev. Growth | 75000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -112.89 |
| EBITDA (p.s.) | 76530.6 |
| Qtrly Earnings Growth | -234.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.36 |
| Dividend | 0 |
| Forward Dividend | 46510 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|